Sugi Predict

Sugi Predict / Compounds / SCHEMBL589706

SCHEMBL589706

SCHEMBL589706

CCS(=O)(=O)c1ccc(-c2cnc(N)nc2N(C)c2ccc3c(C)n[nH]c3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.43
▸ SGK1 O00141 1/20 0.36
▸ PDPK1 O15530 5/20 0.33
▸ CYP1A2 P05177 4/20 0.33
▸ CYP3A4 P08684 4/20 0.33
▸ CYP2C9 P11712 4/20 0.33
▸ AURKA O14965 3/20 0.33
▸ CYP2C19 P33261 3/20 0.33
▸ TGFBR1 P36897 3/20 0.33
▸ CDK2 P24941 2/20 0.33
▸ KDR P35968 2/20 0.33
▸ ROCK1 Q13464 2/20 0.33
▸ AURKB Q96GD4 2/20 0.33
▸ CHUK O15111 1/20 0.33
▸ RPS6KB1 P23443 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ MAP3K5 Q99683 1/20 0.33
▸ PLK4 O00444 2/20 0.32
▸ ROCK2 O75116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589780 0.87 BRD4 (0.36) JAK2
SCHEMBL589060 0.85 SGK1 (0.34) SGK1PDPK1AURKATGFBR1CDK2
SCHEMBL589166 0.80 LRRK2 (0.36) SGK1SCDLRRK2
SCHEMBL588668 0.79 LRRK2 (0.35) SGK1CDK2KDRLRRK2
SCHEMBL589290 0.79 HAO1 (0.34) SGK1KDRLRRK2
SCHEMBL17135503 0.79 JAK2 (0.42) JAK2AURKACDK2KDRROCK1
SCHEMBL589152 0.77 TUBB3 (0.32) —
SCHEMBL588723 0.77 HRH4 (0.37) JAK2
SCHEMBL588725 0.75 DRD2 (0.35) JAK2
SCHEMBL12907430 0.73 JAK2 (0.63) JAK2SGK1PDPK1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311825-B1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2015-10-07 — — EP claimed
EP-2311825-A1 Pyrimidineamines as angiogenesis modulators GlaxoSmithKline LLC (US) 2011-04-20 — — EP claimed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US claimed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US claimed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US claimed
EP-3789027-A1 BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2021-03-10 — — EP disclosed
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2018-01-04 — — US disclosed
EP-3246046-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2017-11-22 — — EP disclosed
EP-2311825-B1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2015-10-07 — — EP disclosed
US-20120277258-A1 Chemical Compounds LEO OSPREY LIMITED (JE) 2012-11-01 — — US disclosed
US-8114885-B2 Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer GLAXOSMITHKLINE LLC (US) 2012-02-14 — — US disclosed
EP-2311825-A1 Pyrimidineamines as angiogenesis modulators GlaxoSmithKline LLC (US) 2011-04-20 — — EP disclosed
US-20100105712-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2010-04-29 — — US disclosed
EP-1343782-B1 PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS SMITHKLINE BEECHAM CORP (US) 2009-05-06 — — EP disclosed
US-20070292513-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-12-20 — — US disclosed
US-20070270427-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-11-22 — — US disclosed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US disclosed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US disclosed
US-7105530-B2 inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 — — US disclosed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators TYMS, TYMP, DPYD JAK2 168/4885SGK1 4755/4885PDPK1 841/4885
US-20070015756-A1 Chemical compounds KDR, FLT4, FLT1 JAK2 35/4885SGK1 2944/4885PDPK1 428/4885
US-20100105712-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 JAK2 35/4885SGK1 2944/4885PDPK1 428/4885
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS WEE2, WEE1, ERBB2 JAK2 25/4885SGK1 204/4885PDPK1 857/4885
US-20120277258-A1 Chemical Compounds KDR, FLT4, FLT1 JAK2 35/4885SGK1 2944/4885PDPK1 428/4885
US-20070270427-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 JAK2 35/4885SGK1 2944/4885PDPK1 428/4885
US-20070292513-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 JAK2 35/4885SGK1 2944/4885PDPK1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.